financetom
Business
financetom
/
Business
/
dynaCERT Gains New and Repeat Orders for its HydraGEN Technology
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
dynaCERT Gains New and Repeat Orders for its HydraGEN Technology
Dec 2, 2024 5:18 AM

07:53 AM EST, 12/02/2024 (MT Newswires) -- dynaCERT (DYA.TO) on Monday said it received new and repeat orders for its HydraGEN Technology from customers in the oil and gas, and mining sectors after successful trials and demand.

From Mexico and Texas, it received orders for seven HG1 units from Thinking Capital, its new dealer there.

dynaCERT also gained repeat orders for 12 HG1 units in November from an oil and gas company, Simple Green, in Western Canada. Moreover, from the Mining sector, GridFix/Net2Zero, an Australian company, and H2Tek from Brazil and Peru, also all placed orders for HydraGEN units.

In related news, the company said it is proceeding with designing multiple Carbon Credit Projects using the recently announced Verra-approved methodology which, it added, "marks a significant milestone" in its ongoing business evolution. The company plans to enhance avoidance of GHG emissions while providing advantages to users of dynaCERT 's HydraGEN Technology derived from such Carbon Credit Projects.

"The growing demand for HydraGEN Technology highlights its tangible benefits to global customers. With the recent approval of our methodology by Verra and progress in launching multiple Carbon Credit Projects, we are positioned to provide even greater value. Our expanded leadership and global reach give me confidence in our continued growth," said dynaCERT Chairman and CEO Jim Payne.

DYA edged down $0.005 at $0.19 last Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Salesforce Stock Wednesday?
What's Going On With Salesforce Stock Wednesday?
Sep 3, 2025
Salesforce, Inc. ( CRM ) is in the spotlight Wednesday ahead of second-quarter earnings due after the market closes. What To Know: Analysts expect Salesforce ( CRM ) to report second-quarter earnings per share of $2.78 and revenue of $10.13 billion. Salesforce ( CRM ) previously guided for second-quarter revenue between $10.11 billion and $10.16 billion. In the company’s first...
Market Chatter: Amazon Probing Allegedly Expensive Repair Bills for Delivery Vans
Market Chatter: Amazon Probing Allegedly Expensive Repair Bills for Delivery Vans
Sep 3, 2025
01:38 PM EDT, 09/03/2025 (MT Newswires) -- Amazon ( AMZN ) is investigating allegedly expensive repair bills for its aging delivery vans that are used by small businesses to deliver packages, Bloomberg reported Wednesday, citing unnamed sources. The small businesses that use the vans to move packages said they can't afford repair bills that can total $20,000 or more, according...
AlphaTON Capital Establishes Specialized Digital Asset Treasury Company; Appoints Brittany Kaiser as CEO
AlphaTON Capital Establishes Specialized Digital Asset Treasury Company; Appoints Brittany Kaiser as CEO
Sep 3, 2025
01:35 PM EDT, 09/03/2025 (MT Newswires) -- AlphaTON Capital (PRTG), formerly known as Portage Biotech ( PRTG ), said Wednesday it has established a specialized digital asset treasury company and secured financing to acquire about $100 million in TON tokens. Additionally, the company said it has appointed Brittany Kaiser as the chief executive officer. The company also named Enzo Villani...
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease
Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease
Sep 3, 2025
01:37 PM EDT, 09/03/2025 (MT Newswires) -- Immunovant ( IMVT ) said Wednesday its proof-of-concept study for batoclimab showed potential for treating patients with uncontrolled Graves' disease, an autoimmune disorder. Six-month off-treatment data in uncontrolled Graves' disease patients treated with batoclimab for 24 weeks showed that around 80% of the patients demonstrated response, resulting in normal thyroid function, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved